Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

Abstract Background OnabotulinumtoxinA is approved for the prevention of headache in those with chronic migraine (CM); however, more clinical data on the risk-benefit profile for treatment beyond one year is desirable. Methods The Chronic Migraine OnabotulinuMtoxinA Prolonged Efficacy open Label (CO...

全面介紹

書目詳細資料

發表在:	The Journal of Headache and Pain
Main Authors:	Andrew M. Blumenfeld, Richard J. Stark, Marshall C. Freeman, Amelia Orejudos, Aubrey Manack Adams
格式:	Article
語言:	英语
出版:	BMC 2018-02-01
主題:	OnabotulinumtoxinA Efficacy Safety Long-term Chronic migraine Prophylaxis
在線閱讀:	http://link.springer.com/article/10.1186/s10194-018-0840-8